⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 1, 2026Open Access

Comprehensive IgM and IgG B-cell epitope profiling of HTLV-1: advancing specific diagnostica assay design

Sérgio Vieira Thaisa Silva Roberta Souza Paloma Pego Salvatore Simone

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to enhance the design of diagnostic assays for HTLV-1 through detailed epitope profiling of IgM and IgG B-cells.
Comprehensive profiling of IgM and IgG epitopes associated with HTLV-1 was performed.
Involvement of external authors in the study design and implementation was noted.
Presentation of findings at the International Symposium on Immunobiologicals.
IgM and IgG epitopes were successfully identified, advancing the understanding of HTLV-1 diagnostics.
Specificity improvements in diagnostic assays were highlighted, although detailed metrics were not provided.

Implication

Assesses specific diagnostic assay design via comprehensive epitope profiling of HTLV-1.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vieira et al. (2026) studied this question.

synapsesocial.com/papers/69fece1db9154b0b82875ccd https://doi.org/10.35259/isi.2026_76215

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-time PCR for detection and typing of HTLV-1/2: development and preliminary performance evaluationOriginal Research · 2026
2Clinical outcomes-dependent IgG epitope profiling in HTLV-1 reveals differential recognition of pathogen-derived antigensOriginal Research · 2026
3In silico design of dengue virus epitopes, recombinant antigens and scfv antibodies for serotype-specific diagnostic developmentOriginal Research · 2026
4A scalable automated framework for validating antibody-antigen recognition through thermal stabilityOriginal Research · 2026
5Development of targeted immunomodulatory VLPs to enhance antigen presentation and potentiate the antitumor immune responseOriginal Research · 2026